Logo image of HOWL

WEREWOLF THERAPEUTICS INC (HOWL) Stock Fundamental Analysis

USA - NASDAQ:HOWL - US95075A1079 - Common Stock

1.67 USD
+0.04 (+2.45%)
Last: 10/14/2025, 8:00:02 PM
1.73 USD
+0.06 (+3.59%)
Pre-Market: 10/15/2025, 4:16:12 AM
Fundamental Rating

2

Taking everything into account, HOWL scores 2 out of 10 in our fundamental rating. HOWL was compared to 536 industry peers in the Biotechnology industry. Both the profitability and financial health of HOWL have multiple concerns. HOWL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HOWL had negative earnings in the past year.
In the past year HOWL has reported a negative cash flow from operations.
HOWL had negative earnings in each of the past 5 years.
HOWL had a negative operating cash flow in each of the past 5 years.
HOWL Yearly Net Income VS EBIT VS OCF VS FCFHOWL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

HOWL's Return On Assets of -79.02% is on the low side compared to the rest of the industry. HOWL is outperformed by 66.98% of its industry peers.
HOWL has a worse Return On Equity (-176.40%) than 64.55% of its industry peers.
Industry RankSector Rank
ROA -79.02%
ROE -176.4%
ROIC N/A
ROA(3y)-36.84%
ROA(5y)-50.48%
ROE(3y)-57.88%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
HOWL Yearly ROA, ROE, ROICHOWL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HOWL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HOWL Yearly Profit, Operating, Gross MarginsHOWL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

HOWL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HOWL has more shares outstanding
The number of shares outstanding for HOWL has been increased compared to 5 years ago.
Compared to 1 year ago, HOWL has an improved debt to assets ratio.
HOWL Yearly Shares OutstandingHOWL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HOWL Yearly Total Debt VS Total AssetsHOWL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -7.68, we must say that HOWL is in the distress zone and has some risk of bankruptcy.
HOWL has a Altman-Z score of -7.68. This is in the lower half of the industry: HOWL underperforms 69.03% of its industry peers.
HOWL has a Debt/Equity ratio of 0.60. This is a neutral value indicating HOWL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.60, HOWL is not doing good in the industry: 72.95% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z -7.68
ROIC/WACCN/A
WACC10.26%
HOWL Yearly LT Debt VS Equity VS FCFHOWL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

HOWL has a Current Ratio of 5.30. This indicates that HOWL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.30, HOWL is in line with its industry, outperforming 57.65% of the companies in the same industry.
HOWL has a Quick Ratio of 5.30. This indicates that HOWL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of HOWL (5.30) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.3
Quick Ratio 5.3
HOWL Yearly Current Assets VS Current LiabilitesHOWL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

HOWL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.48%.
Looking at the last year, HOWL shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-21.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, HOWL will show a small growth in Earnings Per Share. The EPS will grow by 5.63% on average per year.
The Revenue is expected to grow by 118.10% on average over the next years. This is a very strong growth
EPS Next Y2.38%
EPS Next 2Y6.8%
EPS Next 3Y-4.48%
EPS Next 5Y5.63%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y7.36%
Revenue Next 5Y118.1%

3.3 Evolution

HOWL Yearly Revenue VS EstimatesHOWL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
HOWL Yearly EPS VS EstimatesHOWL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HOWL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HOWL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HOWL Price Earnings VS Forward Price EarningsHOWL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HOWL Per share dataHOWL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

HOWL's earnings are expected to decrease with -4.48% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.8%
EPS Next 3Y-4.48%

More info and screens

0

5. Dividend

5.1 Amount

HOWL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WEREWOLF THERAPEUTICS INC

NASDAQ:HOWL (10/14/2025, 8:00:02 PM)

Premarket: 1.73 +0.06 (+3.59%)

1.67

+0.04 (+2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-06 2025-11-06/amc
Inst Owners49.19%
Inst Owner Change0%
Ins Owners1.48%
Ins Owner Change0%
Market Cap76.37M
Analysts88.33
Price Target6.97 (317.37%)
Short Float %1.91%
Short Ratio2.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.04%
Min EPS beat(2)0.47%
Max EPS beat(2)17.61%
EPS beat(4)3
Avg EPS beat(4)4.97%
Min EPS beat(4)-7.8%
Max EPS beat(4)17.61%
EPS beat(8)5
Avg EPS beat(8)9.29%
EPS beat(12)9
Avg EPS beat(12)20%
EPS beat(16)10
Avg EPS beat(16)12.17%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.65%
PT rev (3m)-18.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.47%
EPS NY rev (1m)11.2%
EPS NY rev (3m)12.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.84
P/tB 1.84
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0
BVpS0.91
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -79.02%
ROE -176.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.84%
ROA(5y)-50.48%
ROE(3y)-57.88%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.29%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.3
Quick Ratio 5.3
Altman-Z -7.68
F-Score1
WACC10.26%
ROIC/WACCN/A
Cap/Depr(3y)128.59%
Cap/Depr(5y)197.28%
Cap/Sales(3y)13.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y2.38%
EPS Next 2Y6.8%
EPS Next 3Y-4.48%
EPS Next 5Y5.63%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y7.36%
Revenue Next 5Y118.1%
EBIT growth 1Y-25.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.5%
EBIT Next 3Y-9.75%
EBIT Next 5Y0.98%
FCF growth 1Y-21.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.95%
OCF growth 3YN/A
OCF growth 5YN/A